Darya-Varia Laboratoria Tbk (DVLA) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Darya-Varia Laboratoria Tbk IDR 1,946, price IDR 1,585, upside +22.8%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Darya-Varia Laboratoria Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,170 IDR – 2,276 IDR · fair‑value band 1,277 IDR – 2,853 IDR · the 1,585 IDR price screens below the 1,946 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Darya-Varia Laboratoria Tbk in your weekly email
Every Wednesday you see whether Darya-Varia Laboratoria Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services.
Show more
PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services. The company offers consumer health products, including skin nutrition products under the Natur-E brand; respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brands for nasal congestion, cough, and breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion. It also provides prescription products for various therapeutic areas, including cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women healthcare, antiparasit, vitamin and food supplements, anti fungal, plastic surgery, general surgery, burn, trauma wound, aesthetic medicine, somatik, ear healthcare, and central nerve systems. In addition, the company offers toll manufacturing services for soft gelatin capsules, as well as sterile injections and low volume solid products. It also exports its products. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk operates as a subsidiary of Blue Sphere Singapore Pte. Ltd.
Stock analysis
Darya-Varia Laboratoria Tbk (DVLA) currently trades at 1,585 IDR, while our model-based Fair Value estimate is 1,946 IDR, implying the stock looks roughly 18.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 2,865 IDR per share, and 16 of the 24 models we run sit above the 1,585 IDR price.
Bear case: the Asset-Based group reads lowest at 885.25 IDR, and 8 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 1,277 IDR (bear) to 2,853 IDR (bull), the price of 1,585 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Darya-Varia Laboratoria Tbk reported revenue of 2.2T IDR in FY2025 versus 1.9T IDR in FY2021, a compound +4.1%/yr. Reported net income was 164B IDR in FY2025, compounding +2.9%/yr from FY2021.
Key figures
Market cap 1.8T IDR (≈ $99.2M) · P/E ratio 12.7 · P/S ratio 0.93 · EPS (TTM) 124.99 IDR · Net margin 7.3% · Return on equity 9.2% · Return on assets (EBIT) 9.5% · Operating margin 12.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 13% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 23%, DVLA screens cheaper than that median.
Fair Value models
Bear 1,277 IDRFair Value 1,946 IDRBull 2,853 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (91.77 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic). Over 10 years: +5.5% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+0.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0% vs 4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 9%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +13.3% a year for the price.
Compare Darya-Varia Laboratoria Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 631 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+23% · Above median
Profitability
Return on equity (TTM)9% · Above median
Return on assets5% · Above median
Net margin (TTM)6% · Below median
Operating margin (TTM)12% · Above median
Growth and dividend
Revenue growth9% · Above median
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Darya-Varia Laboratoria Tbk (DVLA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,946 IDR versus a price of 1,585 IDR, about +23% upside (undervalued).
What is the fair value of DVLA?
Our model-based fair value for Darya-Varia Laboratoria Tbk is 1,946 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,585 IDR.
What is the quality score of DVLA?
Darya-Varia Laboratoria Tbk has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Darya-Varia Laboratoria Tbk (DVLA)?
Our model-based price target is the fair value of 1,946 IDR (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 1,277 IDR, optimistic scenario 2,853 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Darya-Varia Laboratoria Tbk stock forecast for 2026?
Our models put fair value at 1,946 IDR, about +23% upside versus a price of 1,585 IDR (undervalued). Cautious scenario 1,277 IDR, optimistic scenario 2,853 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Darya-Varia Laboratoria Tbk (DVLA)?
Darya-Varia Laboratoria Tbk reported trailing-twelve-month revenue of about 2.3T IDR (latest available figure, as of Sep 24, 2026).
What growth is priced into Darya-Varia Laboratoria Tbk (DVLA)?
For today's price to be fair in a discounted-cash-flow model, Darya-Varia Laboratoria Tbk would have to grow free cash flow by +16.3 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of DVLA use?
Our models discount Darya-Varia Laboratoria Tbk at 15.0 %: a base by market capitalisation (micro), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Darya-Varia Laboratoria Tbk that is +16.3 % per year a year over ten years, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Darya-Varia Laboratoria Tbk (DVLA) delivered so far?
Over the past 5 years revenue at Darya-Varia Laboratoria Tbk grew +4.1 % a year. The price currently implies +16.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Darya-Varia Laboratoria Tbk (DVLA) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Darya-Varia Laboratoria Tbk (+16.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Darya-Varia Laboratoria Tbk (DVLA)?
The free-cash-flow yield on the price is 5.29 %: that much free cash flow Darya-Varia Laboratoria Tbk produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Darya-Varia Laboratoria Tbk (DVLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Darya-Varia Laboratoria Tbk it is 1,946 IDR per share (as of Sep 24, 2026), against a price of 1,585 IDR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Darya-Varia Laboratoria Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DVLA trades below its calculated fair value: price 1,585 IDR, fair value 1,946 IDR, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DVLA?
No. The price is what the market pays today (1,585 IDR); the fair value is what the company's own numbers justify (1,946 IDR). For Darya-Varia Laboratoria Tbk the two are 361.36 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Darya-Varia Laboratoria Tbk worth?
The market values Darya-Varia Laboratoria Tbk at about 1.8T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 1,585 IDR; our models calculate a fair value of 1,946 IDR per share.
What do the bullish and bearish scenarios say about DVLA?
Our models span a range for Darya-Varia Laboratoria Tbk: cautious scenario 1,277 IDR, base 1,946 IDR, optimistic 2,853 IDR per share (as of Sep 24, 2026, price 1,585 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DVLA?
Darya-Varia Laboratoria Tbk trades at a price-to-earnings ratio of 12.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,946 IDR is built from several models across several years. Other multiples: P/B 1.2, P/S 0.8, EV/EBITDA 5.7.
How solid is the balance sheet of Darya-Varia Laboratoria Tbk (DVLA)?
Balance-sheet figures for Darya-Varia Laboratoria Tbk (as of Sep 24, 2026): return on equity 9.2%, debt of 0.03 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is DVLA from its 52-week high?
Darya-Varia Laboratoria Tbk trades at 1,585 IDR, about 2% below its 52-week high of 1,613 IDR and 13% above the low of 1,401 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1,946 IDR is for.
Which stocks are comparable to Darya-Varia Laboratoria Tbk?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Darya-Varia Laboratoria Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 1,585 IDR, calculated fair value 1,946 IDR (+23%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DVLA calculated?
We run Darya-Varia Laboratoria Tbk through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,946 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Darya-Varia Laboratoria Tbk currently trades 23 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Darya-Varia Laboratoria Tbk (DVLA)?
The closing price on Sep 24, 2026 was 1,585 IDR. Our model-based fair value is 1,946 IDR, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Darya-Varia Laboratoria Tbk right now?
Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (1,277 IDR to 2,853 IDR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Darya-Varia Laboratoria Tbk (DVLA) come from?
Earnings per share at Darya-Varia Laboratoria Tbk grew +3.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.4 %, EBIT margin −1.3 %, tax rate +0.3 %, residual (interest, one-offs) −0.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Darya-Varia Laboratoria Tbk
How large is the market capitalisation of Darya-Varia Laboratoria Tbk (DVLA)?
The market capitalisation of Darya-Varia Laboratoria Tbk is 1.8T IDR (≈ $99.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Darya-Varia Laboratoria Tbk (DVLA)?
The price-to-sales ratio of Darya-Varia Laboratoria Tbk is 0.93 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Darya-Varia Laboratoria Tbk (DVLA)?
Earnings per share at Darya-Varia Laboratoria Tbk are 124.99 IDR (price ÷ EPS = P/E 12.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Darya-Varia Laboratoria Tbk (DVLA)?
The net margin of Darya-Varia Laboratoria Tbk is 7.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Darya-Varia Laboratoria Tbk (DVLA)?
The return on equity (ROE) of Darya-Varia Laboratoria Tbk is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Darya-Varia Laboratoria Tbk (DVLA)?
On an EBIT basis the return on assets of Darya-Varia Laboratoria Tbk is 9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Darya-Varia Laboratoria Tbk (DVLA)?
The operating margin of Darya-Varia Laboratoria Tbk is 12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Darya-Varia Laboratoria Tbk (DVLA)?
Revenue at Darya-Varia Laboratoria Tbk is growing +9.3% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Darya-Varia Laboratoria Tbk (DVLA)?
Earnings per share at Darya-Varia Laboratoria Tbk are growing −29.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Darya-Varia Laboratoria Tbk (DVLA) hold?
Darya-Varia Laboratoria Tbk holds more cash than debt, 341B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Darya-Varia Laboratoria Tbk in the live analysis
One click puts Darya-Varia Laboratoria Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
